GlassScriptPhysician profile
Sibi Varghese Ipe
NPI 1366607301
$2,031.67
in general payments reported to CMS, 2019-2025
26 companies · $218 in 2025
The $218 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $141 · 2022: $1,013 · 2023: $329 · 2024: $331 · 2025: $218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $798 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $797.73 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $617.67 | 2022-2023 | Xospata |
| Incyte Corporation | $467.64 | 2021-2025 | Jakafi, Monjuvi, Niktimvo |
| Merck Sharp & Dohme LLC | $150.17 | 2021-2025 | Welireg, Keytruda |
| Genzyme Corporation | $67.97 | 2022-2024 | |
| Jazz Pharmaceuticals INC. | $67.44 | 2021-2022 | |
| Adc Therapeutics America, INC. | $63.26 | 2024-2025 | |
| Blueprint Medicines Corporation | $61.53 | 2022-2023 | Ayvakit |
| Rigel Pharmaceuticals, INC. | $51.24 | 2022-2023 | Rezlidhia, Tavalisse |
| Servier Pharmaceuticals LLC | $43.96 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.02 | 2022-2023 | Livtencity |
| Syndax Pharmaceuticals, INC. | $41.79 | 2025 | |
| Glaxosmithkline, LLC. | $37.49 | 2022 | |
| Janssen Biotech, INC. | $32.07 | 2022 | |
| Sobi, INC | $31.68 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $29.90 | 2024 | Libtayo |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adaptive Biotechnologies Corporation | $29.84 | 2023 | Clonoseq |
| Geron Corporation | $25.06 | 2025 | Rytelo |
| Janssen Scientific Affairs, LLC | $24.06 | 2024 | Carvykti, Darzalex |
| Dova Pharmaceuticals | $23.18 | 2021 | |
| Karyopharm Therapeutics INC. | $19.77 | 2024 | Xpovio |
| Legend Biotech USA INC. | $19.56 | 2023 | Carvykti |
| Menarini Silicon Biosystems, INC. | $19.28 | 2024 | |
| Mirati Therapeutics, INC. | $18.40 | 2024 | Krazati |
| Acrotech Biopharma INC. | $16.87 | 2023 | Beleodaq |
| Genmab U.S., INC. | $15.37 | 2024 | Epkinly |
| Cti Biopharma Corp. | $14.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sibi Ipe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.